Scroll

darifenacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
muscarinic receptors antagonists	784	133099-04-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: enablex darifenacin darifenacin hydrobromide emselex	a competitive muscarinic receptor antagonist with greater affinity for the M3 receptor than for the other known muscarinic receptors, M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function Molecular weight: 426.56 Formula: C28H30N2O2 CLOGP: 4.28 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 55.56 ALOGS: -6.16 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

enablex
darifenacin
darifenacin hydrobromide
emselex

a competitive muscarinic receptor antagonist with greater affinity for the M3 receptor than for the other known muscarinic receptors, M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function

Molecular weight: 426.56
Formula: C28H30N2O2
CLOGP: 4.28
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 55.56
ALOGS: -6.16
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	17 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 22, 2004	EMA	Merus Labs Luxco S.a R.L.
Dec. 22, 2004	FDA	WARNER CHILCOTT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia viral	494.24	33.96	108	3236	7814	63477864
Soft tissue disorder	394.19	33.96	81	3263	4341	63481337
Herpes zoster	353.36	33.96	140	3204	82322	63403356
Liver function test abnormal	238.46	33.96	91	3253	48090	63437588
Oral pain	217.01	33.96	74	3270	28320	63457358
Leukopenia	209.57	33.96	95	3249	77195	63408483
Fibromyalgia	205.96	33.96	95	3249	80325	63405353
Blood cholesterol increased	194.79	33.96	96	3248	93936	63391742
Asphyxia	192.35	33.96	48	3296	6133	63479545
Peripheral swelling	175.69	33.96	130	3214	265812	63219866
Arthritis	173.04	33.96	95	3249	115826	63369852
Arteriosclerosis coronary artery	168.53	33.96	46	3298	8327	63477351
Synovitis	157.15	33.96	106	3238	186812	63298866
Anaemia	103.26	33.96	100	3244	293330	63192348
Infection	97.76	33.96	87	3257	229086	63256592
Joint swelling	88.68	33.96	97	3247	327569	63158109
Tenderness	81.36	33.96	34	3310	22544	63463134
Therapeutic product effect incomplete	64.43	33.96	53	3291	125003	63360675
Soft tissue swelling	50.61	33.96	12	3332	1232	63484446
Drug ineffective	43.09	33.96	136	3208	1044629	62441049
Complement factor C4 decreased	35.92	33.96	7	3337	283	63485395
Complement factor C3 decreased	35.73	33.96	7	3337	291	63485387
Neuralgia	35.10	33.96	20	3324	25906	63459772

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Duplicate therapy error	50.47	50.15	7	364	174	34956386

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia viral	329.92	35.70	74	2720	9084	79732510
Soft tissue disorder	238.88	35.70	48	2746	3467	79738127
Herpes zoster	196.61	35.70	85	2709	92998	79648596
Asphyxia	186.15	35.70	49	2745	11671	79729923
Arteriosclerosis coronary artery	152.79	35.70	46	2748	17770	79723824
Fibromyalgia	136.45	35.70	59	2735	64281	79677313
Blood cholesterol increased	124.61	35.70	60	2734	83660	79657934
Liver function test abnormal	120.14	35.70	54	2740	64421	79677173
Oral pain	119.20	35.70	44	2750	31754	79709840
Synovitis	114.34	35.70	69	2725	150665	79590929
Peripheral swelling	110.01	35.70	84	2710	269533	79472061
Arthritis	101.29	35.70	58	2736	114822	79626772
Leukopenia	97.86	35.70	57	2737	116456	79625138
Tenderness	78.67	35.70	30	2764	23612	79717982
Therapeutic product effect incomplete	70.83	35.70	50	2744	141595	79599999
Joint swelling	59.20	35.70	61	2733	288585	79453009
Infection	54.88	35.70	54	2740	241658	79499936
Soft tissue swelling	47.85	35.70	11	2783	1490	79740104
Anaemia	45.28	35.70	66	2728	444949	79296645
Arthralgia	39.34	35.70	71	2723	571732	79169862
Duplicate therapy error	38.37	35.70	7	2787	300	79741294
Neuralgia	38.01	35.70	20	2774	33364	79708230
Complement factor C4 decreased	37.45	35.70	7	2787	343	79741251
Complement factor C3 decreased	36.91	35.70	7	2787	371	79741223

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04BD10	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence
FDA MoA	N0000000125	Cholinergic Muscarinic Antagonists
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
FDA EPC	N0000175700	Cholinergic Muscarinic Antagonist
CHEBI has role	CHEBI:48876	muscarinic antagonists
CHEBI has role	CHEBI:53784	antispasmodics

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Urgent desire to urinate	indication	75088002
Urge incontinence of urine	indication	87557004
Bladder muscle dysfunction - overactive	indication	236633002
Increased Urinary Frequency	indication
Angioedema	contraindication	41291007	DOID:1558
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Myasthenia gravis	contraindication	91637004	DOID:437
Gastrointestinal obstruction	contraindication	126765001
Acute constipation	contraindication	197119006
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Retention of urine	contraindication	267064002
Gastric retention	contraindication	307227006
Angle-closure glaucoma	contraindication	392291006	DOID:13550

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.6	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Kd	9.52	CHEMBL	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	7.21	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		IC50	4.60	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.30	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	7.60	CHEMBL
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.10	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.64	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		IC50	6.50	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	7.20	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR		ACM3_RAT		Ki	8.60	CHEMBL

External reference:

ID	Source
D01699	KEGG_DRUG
133099-07-7	SECONDARY_CAS_RN
136198	RXNORM
4024903	VANDF
C0529351	UMLSCUI
CHEBI:391960	CHEBI
CHEMBL1346	ChEMBL_ID
CHEMBL1200935	ChEMBL_ID
DB00496	DRUGBANK_ID
C101207	MESH_SUPPLEMENTAL_RECORD_UI
444031	PUBCHEM_CID
321	IUPHAR_LIGAND_ID
7153	INN_ID
APG9819VLM	UNII
19114	MMSL
64038	MMSL
d05422	MMSL
008802	NDDF
008812	NDDF
416140008	SNOMEDCT_US
416385001	SNOMEDCT_US
426766002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-202	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-202	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-202	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-203	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-203	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-203	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections
Darifenacin	Human Prescription Drug Label	1	16571-767	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	16571-768	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-276	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-276	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-277	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	33342-277	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-223	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-223	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-224	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	46708-224	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-067	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	27 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-067	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	27 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-068	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	27 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	52605-068	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	27 sections
Enablex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5363	TABLET, EXTENDED RELEASE	15 mg	ORAL	NDA	25 sections
Enablex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5704	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	NDA	25 sections
DARIFENACIN	Human Prescription Drug Label	1	62332-223	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
DARIFENACIN	Human Prescription Drug Label	1	62332-224	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	65862-861	TABLET, FILM COATED, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	26 sections
Darifenacin	Human Prescription Drug Label	1	65862-862	TABLET, FILM COATED, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-431	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	24 sections
Darifenacin	HUMAN PRESCRIPTION DRUG LABEL	1	69097-432	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	24 sections
Darifenacin 7.5 mg	HUMAN PRESCRIPTION DRUG LABEL	1	70700-182	TABLET, EXTENDED RELEASE	7.50 mg	ORAL	ANDA	25 sections
Darifenacin 15 mg	HUMAN PRESCRIPTION DRUG LABEL	1	70700-183	TABLET, EXTENDED RELEASE	15 mg	ORAL	ANDA	25 sections